capecitabine Articles
India's Cipla cuts prices of three cancer drugs
12 November 2012
Mylan enters settlement and license deal with Roche over Xeloda
21 September 2011
Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche
28 July 2010
Switzerland’s Roche eyes up China’s potential
2 March 2010
Mixed fortunes for Roche’s Avastin; Xeloda recommended by EU
26 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
NICE rejects Roche’s bowel cancer drug Avastin for a second time
27 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
ECCO/ESMO: new data show Merck Serono ’s Erbitux extends survival in colorectal and lung cancers
28 September 2009
Pfizer halts Sutent Ph III breast cancer study
3 June 2009
Avastin boosts PFS 36% in HER2-negative patients
1 June 2009
Elderly Xeloda patients "twice as likely to die"
15 May 2009
B-MS withdraws Ixempra MAA
30 March 2009
AGI's CID drug shows benefit at higher dose
23 March 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
Roche GI cancer therapy as good as FOLFOX
26 January 2009
Xeloda plus chemo reduces recurrence 34%
22 December 2008
B-MS' Ixempra increases PFS in triple negative BC
22 December 2008
CHMP denies B-MS and Santhera drugs
1 December 2008
Avastin increases PFS in advanced breast cancer
1 December 2008
Ph II study of ImClone's IMC-A12 starts enrolling patients
24 November 2008
Roche gets Chinese approval for Xeloda
8 September 2008
Roche's 1st-half net profit sees downturn
28 July 2008
Xeloda better than colon cancer gold-standard
7 July 2008
GSK's Tyverb gets European approval
23 June 2008
Herceptin works in different disease stages
9 June 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
Delay to EU approval of GSK
31 March 2008
Japan stock market week to March 10, 2008
17 March 2008
Tokyo stocks in the week to February 18, 2008
25 February 2008
UK's NICE asked to develop new clinical health guidance for DoH
18 February 2008
Roche's Xeloda gets EC OK for bowel cancer
14 February 2008
EC grants Xeloda broad approval for mCRC
11 February 2008
Eisai changes US E7389 filing schedule
11 February 2008
EC broadens Avastin use in mCRC indication
4 February 2008
Neoadjuvant Xeloda reduces breast tumor size in Ph II trial
24 December 2007
GSK's Tyverb gets nod from CHMP
24 December 2007
Xeloda and Avastin to get expanded indications
24 December 2007
FDA OKs Ixempra for breast cancer
22 October 2007
14th annual ECCO conference hears exciting data on combination therapy with biologics
8 October 2007
X-ACT confirms Xeloda efficacy in bowel cancer
8 October 2007
Stock Commentary - New York week to Sept 10, 2007
17 September 2007
Scottish cancer patients offered Xeloda
17 September 2007
B-MS' ixabepilone NDA accepted by FDA
2 July 2007
GSK's Tykerb shows potential in breast cancer
11 June 2007
Japan stock market week to April 16, 2007
23 April 2007
EC expands indication for Roche's Avastin
9 April 2007
GSK submits lapatinib NDA in Japan
9 April 2007
Roche submits new Xeloda regimen to FDA
2 April 2007
Clarification to FDA's Tykerb approval
26 March 2007
Japan stock market week to Feb 26, 2007
5 March 2007
Xeloda gets nod for stomach cancer in Europe
5 March 2007
Roche posts record 2006 net profits, boosted by cancer drugs
12 February 2007
Xeloda plus Avastin show clinical benefit
22 December 2006
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
GSK's Tykerb under EMEA review
16 October 2006
FDA to review Tykerb as breast cancer therapy
25 September 2006
New study validates Roche's XELOX in colorectal cancer
7 August 2006
Xeloda filed in EU for stomach cancer
31 July 2006
GSK's Tykerb 'to rival Herceptin,' Ph III study
12 June 2006
Roche's Xeloda sees strong Ph III data
12 June 2006
Lilly's enzastaurin: good combo drug at Ph I
12 June 2006
GPC starts Ph I study of satraplatin plus Xeloda
22 May 2006
Roche's 1st-qtr 2006 sales rise 22%
8 May 2006
Japan stock market week to April 17, 2006
24 April 2006
Roche's Xeloda performs well in Ph III
17 April 2006
Roche suspends Avastin AVANT study
20 February 2006
Scotland OKs Xeloda but fears in England/Wales
15 August 2005
Roche Rx sales grow three times world rate
25 July 2005
Roche's Xeloda "could replace 5-FU/LV"
11 July 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
